Microbot Medical Sees Unusually High Options Volume (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 2,704 call options on the company. This represents an increase of approximately 122% compared to the average volume of 1,216 call options.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Microbot Medical in a report on Thursday, April 10th.

Hedge Funds Weigh In On Microbot Medical

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 10,442 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Microbot Medical in the 4th quarter worth approximately $118,000. Virtu Financial LLC bought a new stake in Microbot Medical during the first quarter worth approximately $42,000. Finally, Goldman Sachs Group Inc. acquired a new position in Microbot Medical during the first quarter valued at approximately $57,000. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Trading Down 0.8%

NASDAQ MBOT traded down $0.02 during trading on Thursday, reaching $2.48. The company's stock had a trading volume of 717,841 shares, compared to its average volume of 1,727,889. The stock has a market capitalization of $90.22 million, a PE ratio of -3.10 and a beta of 1.14. The business has a 50-day moving average price of $2.42 and a 200-day moving average price of $1.84. Microbot Medical has a 1-year low of $0.82 and a 1-year high of $3.38.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.07. As a group, analysts expect that Microbot Medical will post -0.71 earnings per share for the current year.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.